Detalhe da pesquisa
1.
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Lancet
; 401(10394): 2124-2137, 2023 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37302395
2.
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet
; 390(10099): 1048-1060, 2017 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28779963
3.
Targeted radiotherapy for early breast cancer - Authors' reply.
Lancet
; 391(10115): 27-28, 2018 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29323651
4.
Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.
Cancer Res
; 63(13): 3612-8, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12839949
5.
Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.
Br J Radiol
; 88(1056): 20150453, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26492402
6.
Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study.
Anticancer Res
; 22(1A): 69-74, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12017336
7.
Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma.
Mod Pathol
; 16(8): 778-85, 2003 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12920222